India approves first dengue vaccine amid rising disease burden

India Approves First Dengue Vaccine QDENGA Amid Rising Disease Burden

Theindiapostdaily.com – India has officially approved its first dengue vaccine, QDENGA, marking a significant milestone in the fight against the mosquito-borne illness. Developed by Takeda Pharmaceutical Co.’s Indian subsidiary, Takeda Biopharmaceuticals India Pvt. Ltd., the vaccine received regulatory clearance under the CT-20, New Drugs and Clinical Trials (NDCT) Rules, 2019, following endorsement by the Drug Controller General of India (DCGI). This decision comes as dengue cases in the country have surged, prompting urgent calls for scalable and accessible prevention solutions.

Understanding Dengue and Its Global Impact

Dengue is a viral disease transmitted primarily through the Aedes aegypti mosquito, affecting over 125 nations worldwide. India, a hotspot for the disease, accounts for nearly one-third of the global dengue burden, with annual infections estimated to be in the tens of millions due to underreporting and the challenges of tracking urban outbreaks. The rapid spread of the disease, coupled with climate change and urbanization, has intensified the need for effective interventions. India’s approval of QDENGA is a strategic response to this growing public health threat, aiming to reduce the strain on healthcare systems and improve outcomes for affected populations.

QDENGA, a tetravalent live-attenuated vaccine, has been designed to protect against all four serotypes of the dengue virus. Unlike some other vaccines that require pre-screening for prior exposure, QDENGA is administered without such checks, making it a versatile option for widespread use. The two-dose regimen, spaced three months apart, is given subcutaneously and has been prequalified by the World Health Organization (WHO), which facilitates its integration into global health initiatives and procurement programs. This approval underscores the vaccine’s potential to address the unique challenges of dengue epidemiology in India.

Seven-Year Clinical Data Validates Efficacy and Safety

Key to the approval of QDENGA is the robust clinical data supporting its efficacy over a seven-year period. Dr. Mahender Nayak, head of Intercontinental Markets at Takeda India, highlighted that the vaccine demonstrated consistent effectiveness against dengue infection and hospitalization across all serotypes. Since its launch in 2022, QDENGA has been adopted in 43 countries, with over 32 million doses distributed globally. In India, the vaccine’s availability is expected to complement existing measures such as vector control and community surveillance, enhancing the nation’s ability to manage outbreaks.

The approval process relied on data from 19 phase I, II, and III clinical trials, involving more than 28,000 participants across both endemic and non-endemic regions. A pivotal phase III trial, known as TIDES (DEN-301), evaluated the vaccine in over 20,000 individuals across eight countries. The results indicated an 80.2% efficacy against virologically confirmed dengue at 12 months post-second dose, with efficacy against hospitalization rising to 90.4% after 18 months and 84.1% at 4.5 years. These findings, combined with real-world evidence and ongoing pharmacovigilance, reinforce QDENGA’s role in preventing severe dengue complications.

India’s Role in Global Dengue Prevention

India’s decision to approve QDENGA places the nation at the forefront of dengue vaccination efforts in Asia. Dr. Goh Choo Beng, medical affairs lead for Southeast Asia and India, emphasized that the country’s substantial dengue burden, with all four serotypes circulating in multiple regions, necessitates a proactive approach. The vaccine’s inclusion in the national immunization program will enable targeted interventions, particularly in high-risk areas such as urban slums and tropical regions where mosquito populations thrive.

With the vaccine now available, Takeda plans to collaborate with local health authorities and healthcare providers to ensure a smooth rollout. This partnership will focus on training medical staff, establishing distribution networks, and raising awareness about the benefits of vaccination. India’s approval of QDENGA is not only a testament to the vaccine’s scientific merit but also a reflection of the country’s commitment to combating infectious diseases through innovation and accessibility. The vaccine’s potential to reduce hospitalizations and mortality rates is a critical step in improving public health outcomes.

India approves first dengue vaccine in a landmark move that addresses the nation’s growing health challenges. The vaccine’s approval comes amid rising dengue cases, which have placed significant pressure on healthcare resources. QDENGA’s two-dose regimen offers a practical solution, as it can be administered even in remote areas with limited infrastructure. This flexibility is vital for achieving equitable vaccine distribution, especially in regions where routine immunization programs face logistical hurdles. By prioritizing accessibility, India aims to protect millions of citizens from the disease’s devastating effects.

As the first dengue vaccine approved in India, QDENGA represents a breakthrough in the country’s public health strategy. Its development and approval highlight the importance of international collaboration in addressing diseases with global implications. The vaccine’s safety profile, confirmed through extensive trials, ensures that it is suitable for a wide range of age groups, from children to adults. With ongoing research and real-world monitoring, QDENGA is positioned to become a cornerstone of India’s efforts to combat dengue in the years to come. This approval is a critical component of the nation’s plan to mitigate the disease’s impact and safeguard vulnerable populations.